Summit Therapeutics Inc. (SMMT)
Healthcare • Biotechnology
StockNasdaqGMUnited StatesUS86627T1088
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Summit Therapeutics Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:29. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 22 Feb 2027 16:00 | -0.22 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.20 | -0.19 | +2.5% | Beat |
| 23 Jul 2026 16:00 | -0.21 | -0.21 | +2.1% | Beat |
| 30 Apr 2026 17:00 | -0.21 | -0.18 | +14.3% | Beat |
| 23 Feb 2026 16:00 | -0.01 | -0.21 | -1,386.3% | Miss |
| 20 Oct 2025 06:00 | -0.04 | -0.23 | -429.3% | Miss |
| 11 Aug 2025 17:00 | -0.07 | -0.57 | -721.4% | Miss |
| 01 May 2025 16:00 | -0.07 | -0.07 | +0.7% | In line |
| 24 Feb 2025 06:00 | -0.06 | -0.06 | -3.3% | Miss |
| 30 Oct 2024 07:00 | -0.05 | -0.06 | -23.1% | Miss |
| 06 Aug 2024 07:00 | -0.05 | -0.07 | -46.9% | Miss |
| 01 May 2024 07:00 | -0.05 | -0.05 | -1.9% | Miss |
| 15 Nov 2021 08:00 | -0.21 | -0.15 | +28.7% | Beat |
| 11 Aug 2021 08:00 | -0.13 | -0.19 | -51.0% | Miss |
| 17 May 2021 16:00 | -0.12 | -0.21 | -72.1% | Miss |
| 17 Mar 2021 07:00 | -0.16 | -0.13 | +17.9% | Beat |
| 16 Nov 2020 16:00 | -0.19 | -0.19 | -1.6% | Miss |
| 29 Sep 2020 07:00 | -0.06 | -0.18 | -184.1% | Miss |
| 02 Jun 2020 16:00 | -0.02 | -0.01 | +50.0% | Beat |
| 30 Apr 2020 08:00 | -0.03 | -0.03 | -9.1% | Miss |
| 11 Dec 2018 07:00 | -0.12 | -0.50 | -327.4% | Miss |
| 20 Sep 2018 07:00 | -0.30 | 1.83 | +717.8% | Beat |
| 05 Jun 2018 07:00 | -0.10 | -0.40 | -300.0% | Miss |
| 11 Apr 2018 07:00 | -0.09 | -0.80 | -788.9% | Miss |
| 06 Dec 2017 07:00 | -0.10 | -0.15 | -50.0% | Miss |
| 31 Aug 2017 07:00 | 0.25 | 0.85 | +240.0% | Beat |
| 14 Jun 2017 07:00 | -0.14 | -0.40 | -185.7% | Miss |
| 29 Mar 2017 08:00 | -0.12 | -0.40 | -230.6% | Miss |
| 15 Dec 2016 07:00 | -0.02 | -0.40 | -2,005.3% | Miss |
| 08 Sep 2016 07:00 | -0.10 | -0.50 | -400.0% | Miss |
| 02 Jun 2016 07:00 | -0.27 | -0.45 | -67.9% | Miss |
| 10 May 2016 07:00 | -0.08 | -0.08 | -2.5% | Miss |
| 17 Dec 2015 07:00 | -0.10 | -0.08 | +17.5% | Beat |
| 27 Aug 2015 07:00 | -0.07 | -0.07 | +6.7% | Beat |
| 11 Jun 2015 07:00 | -0.06 | -0.06 | 0.0% | In line |
| 06 May 2015 07:00 | -0.07 | -0.07 | 0.0% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -1.1B | — | -1.44 | -364.5% | -323.6M |
| 2024 | 0 | — | -221.3M | — | -0.31 | +68.7% | -142.2M |
| 2023 | 0 | -100.0% | -614.9M | — | -0.99 | -141.5% | -76.9M |
| 2022 | 705K | — | -78.8M | -11,174.8% | -0.41 | — | -42.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 15.99 | 18.15 | 14.12 | 14.27 | -11.01% | 47,265,328 | |
| Oct 2026 | 16.82 | 18.33 | 14.37 | 16.03 | -5.20% | 115,422,100 | |
| Sep 2026 | 13.38 | 19.09 | 13.37 | 16.91 | +24.16% | 158,816,000 | |
| Aug 2026 | 13.11 | 15.75 | 12.07 | 13.62 | +4.61% | 113,786,200 | |
| Jul 2026 | 14.59 | 16.05 | 12.25 | 13.02 | -10.64% | 84,084,900 | |
| Jun 2026 | 16.70 | 16.84 | 12.55 | 14.57 | -16.93% | 153,371,800 | |
| May 2026 | 16.02 | 19.42 | 15.14 | 17.54 | -18.27% | 93,864,700 | |
| Apr 2026 | 19.17 | 29.23 | 18.38 | 21.46 | +13.19% | 82,083,500 | |
| Mar 2026 | 16.00 | 19.00 | 14.60 | 18.96 | +14.29% | 56,851,800 | |
| Feb 2026 | 14.21 | 16.80 | 13.83 | 16.59 | +14.57% | 44,519,000 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High? (opens in a new tab) Zacks · 10 Nov 2026 13:55
- Summit Therapeutics (SMMT) Stock Looks Richly Priced On Its 7x Run (opens in a new tab) Simply Wall St. · 10 Nov 2026 00:21
- Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? (opens in a new tab) Benzinga · 09 Nov 2026 12:51
- FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week (opens in a new tab) Stocktwits · 09 Nov 2026 10:23
- Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘ (opens in a new tab) Stocktwits · 09 Nov 2026 01:16
- SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus (opens in a new tab) Zacks · 05 Nov 2026 11:37
- Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 (opens in a new tab) 04 Nov 2026 21:36
- Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate (opens in a new tab) Benzinga · 04 Nov 2026 18:00
- Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal (opens in a new tab) Simply Wall St. · 30 Oct 2026 21:08
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (opens in a new tab) MarketBeat · 26 Oct 2026 16:05
- Lunit and Summit to evaluate pathology platform for tumour analysis (opens in a new tab) Pharmaceutical Technology · 26 Oct 2026 11:00
- Summit Expands Ivonescimab Development Into Biliary Tract Cancer (opens in a new tab) Zacks · 22 Oct 2026 14:49
- Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? (opens in a new tab) Zacks · 21 Oct 2026 15:00
- Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus (opens in a new tab) Simply Wall St. · 17 Oct 2026 08:12
- AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos (opens in a new tab) Quartz · 06 Oct 2026 12:44
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 15.08 USD
- Market cap
- 12.1B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow SMMT and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.